Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India

NCT03070704 · Withdrawn

Last updated 2026-05-28

This study observed the long-term safety of the diabetes medication Xultophy™ in adults with type 2 diabetes during routine medical care in India.

Status Withdrawn Stopped before any participant enrolled.

Type Observational

Who can join Ages 18+ · all sexes

Timeline Started 2017-08 · est. completion 2019-08

What this study is testing ClinicalTrials.gov NCT03070704 ↗

Description as written by the study sponsor.

This study is conducted in Asia. The aim of this study is to evaluate long term safety and efficacy in patients with type 2 diabetes mellitus in routine clinical practice in India.

Treatments tested

insulin degludec/liraglutide Drug

Patients will be treated with commercially available Xultophy™ (insulin degludec / liraglutide) according to routine clinical practice at the discretion of the treating physician

Main thing measured	Incidence of treatment emergent Adverse Events (AEs)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03070704 ↗